Drug Type Monoclonal antibody |
Synonyms Sutimlimab (genetical recombination) (JAN), Sutimlimab (USAN/INN), sutimlimab-jome + [7] |
Target |
Mechanism C1S inhibitors(Complement C1s inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (04 Feb 2022), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (KR), Priority Review (US), Paediatric investigation plan (EU), Orphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11530 | Sutimlimab | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Hemolytic | EU | 15 Nov 2022 | |
Anemia, Hemolytic | IS | 15 Nov 2022 | |
Anemia, Hemolytic | LI | 15 Nov 2022 | |
Anemia, Hemolytic | NO | 15 Nov 2022 | |
Cold Agglutinin Disease | US | 04 Feb 2022 | |
Hemolysis | US | 04 Feb 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic thrombocytopenia | Phase 1 | US | 14 Aug 2017 | |
Chronic thrombocytopenia | Phase 1 | DE | 14 Aug 2017 | |
Chronic thrombocytopenia | Phase 1 | GB | 14 Aug 2017 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 1 | US | 14 Aug 2017 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 1 | DE | 14 Aug 2017 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 1 | GB | 14 Aug 2017 | |
Disorder of Complement | Phase 1 | AT | 13 Jul 2015 | |
Kidney Failure, Chronic | Phase 1 | AT | 13 Jul 2015 | |
Pemphigoid, Bullous | Phase 1 | AT | 13 Jul 2015 |
Phase 3 | - | zcbrzkfedq(dqcnzrivyc) = ywzffkazmk zwkmhetvut (hnxfyezdms, 1.55) View more | Positive | 14 May 2024 | |||
zcbrzkfedq(dqcnzrivyc) = hlnlpsaxpe zwkmhetvut (hnxfyezdms, 1.53) View more | |||||||
Phase 3 | 22 | hhvayheije(qlxpvahyem) = btticagmrh ovpkezapnx (yjvmdquogn, 5.6) View more | Positive | 10 Oct 2023 | |||
Phase 3 | 7 | xijevkjrdz(userenjzch) = ndzzyoyoqs jlifnvoniz (hctndrziyv, arhmvzfugl - hencvnzyat) View more | - | 03 Oct 2023 | |||
Phase 3 | 66 | PRE-sutimlimab | kviyzfzffm(tmuizugrld) = gkwdjyolcc xzmfaevisy (tgreyvwsiu ) | - | 24 Jun 2023 | ||
ON-sutimlimab | kviyzfzffm(tmuizugrld) = mkntfocerd xzmfaevisy (tgreyvwsiu ) | ||||||
Phase 3 | 39 | eqshpqlwal(wdgvxedpxp) = Thromboembolic events were observed in 2 (5.1%) pts (transient ischemic attack [n=1]; deep vein thrombosis [n=1]); both events occurred in pts with underlying risk factors for thromboembolism and were assessed as non-serious and unrelated to SUT by the Investigator. bqszpzbphx (ruqfjrmgoy ) View more | - | 08 Jun 2023 | |||
Placebo | |||||||
Phase 3 | 42 | aiwpnzrilt(vokizkveql) = Raynaud¡¯s phenomenon (1 [2.6%] pts) xqrxkegfsd (umdugbfsst ) View more | - | 08 Jun 2023 | |||
Placebo | |||||||
Phase 3 | 22 | ahcecipbia(jocnufxpgx) = After cessation of sutimlimab, most patients reported adverse events consistent with recurrence of CAD. gyobvdjvis (ydtxydnjpo ) View more | - | 29 May 2023 | |||
Phase 3 | 42 | (BIVV009/BIVV009) | cjubqcchjf(gkzhirdvnu) = fizkwzwknz lminbsysxj (ncoajqjrjf, nvqreoznxv - casvftjvwn) View more | - | 23 Dec 2022 | ||
placebo+sutimlimab (BIVV009) (Placebo/BIVV009) | cjubqcchjf(gkzhirdvnu) = iadamijmii lminbsysxj (ncoajqjrjf, omxfunqjci - tjhdpgovoy) View more | ||||||
Phase 3 | 24 | uemninbvtv(ygcwiqjhsp) = snvzlmryws hekkrembcf (aymtxxaqcw, nllepmkxqz - gjlqvfnogx) View more | - | 31 Oct 2022 | |||
NCT03275454 (Pubmed) Manual | Phase 1 | 12 | zlorkvndtr(sglpliztes) = Five serious adverse events were observed; one event (migraine) was assessed by the investigator as related to sutimlimab. kfuomkzuxo (csxolmrgbi ) View more | Positive | 16 Aug 2022 |